Who is sponsoring NCT05059769?

NCT05059769 is sponsored by Dongying Zhang.

What condition does NCT05059769 study?

NCT05059769 studies Heart Failure With Preserved Ejection Fraction.

Is NCT05059769 still recruiting?

NCT05059769 is currently status unknown. Last updated 28 September 2021.

Last reviewed 2021-09-28 · How we verify

NCT05059769

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Relationship Between Ambulatory Arterial Stiffness Index and Left Ventricular Diastolic Function in Patients With HFpEF

Status unknown Last updated 28 September 2021

What this trial tests

trial in Heart Failure With Preserved Ejection Fraction in 200 participants. Status unknown.

Timeline

10 October 2020

Primary endpoint
31 December 2021

30 April 2022

Quick facts

Lead sponsor	Dongying Zhang
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	10 October 2020
Primary completion	31 December 2021
Estimated completion	30 April 2022
Sites	1 location across China

Conditions studied

Heart Failure With Preserved Ejection Fraction — all drugs for Heart Failure With Preserved Ejection Fraction →

Sponsor

Dongying Zhang

Who can join

18 and older, any sex, with Heart Failure With Preserved Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Heart failure with preserved ejection fraction (HFpEF) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and arteriosclerosis. Ambulatory arterial stiffness index (AASI) is associated with arteriosclerosis and hypertension. There is no report on whether AASI is associated with left ventricular diastolic dysfunction in patients with HFpEF.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The relationship between ambulatory arterial stiffness index and left ventricular diastolic dysfunction in HFpEF: a prospective observational study.
Zhang H, Hu W, Wang Y, Liu J, et al · · 2022 · cited 3× · PMID 35655132 · DOI 10.1186/s12872-022-02679-6

Verify or expand the search:

Other recruiting trials for Heart Failure With Preserved Ejection Fraction

Currently open trials in the same condition.

NCT06833138 — Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillati · NA · recruiting
NCT06937827 — Transitions of Care Clinic (TOCC) · NA · recruiting
NCT07037459 — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity · Phase 3 · recruiting
NCT06702501 — The PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF) · NA · recruiting
NCT06616974 — A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction · Phase 2 · recruiting

Other Dongying Zhang trials

Trials by the same sponsor.

NCT06812546 — Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction · Phase 4 · not yet recruiting
NCT06604611 — Colchicine in Patients With Heart Failure With Preserved Ejection Fraction and Inflammation · Phase 4 · not yet recruiting
NCT05068934 — The Relationship Between Epicardial Fat Tissue and Cardiac Function in HFpEF Patients · completed
NCT06245980 — Role of SGLT2I in Patients With Myocardial Infarction · unknown
NCT03984071 — The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05059769 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dongying Zhang
Last refreshed: 28 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05059769.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing